1 February 2024 false No description of principal activity Taxfiler 2024.6 NI709560 business:PrivateLimitedCompanyLtd 2024-02-01 2025-02-28 NI709560 2024-01-31 NI709560 2024-02-01 2025-02-28 NI709560 business:AuditExemptWithAccountantsReport 2024-02-01 2025-02-28 NI709560 business:FilletedAccounts 2024-02-01 2025-02-28 NI709560 2025-02-28 NI709560 business:Director1 2024-02-01 2025-02-28 NI709560 business:Director2 2024-02-01 2025-02-28 NI709560 business:Director3 2024-02-01 2025-02-28 NI709560 business:RegisteredOffice 2024-02-01 2025-02-28 NI709560 core:WithinOneYear 2025-02-28 NI709560 core:ShareCapital core:PreviouslyStatedAmount 2025-02-28 NI709560 core:SharePremium core:PreviouslyStatedAmount 2025-02-28 NI709560 core:RetainedEarningsAccumulatedLosses core:PreviouslyStatedAmount 2025-02-28 NI709560 core:PreviouslyStatedAmount 2025-02-28 NI709560 business:SmallEntities 2024-02-01 2025-02-28 NI709560 countries:NorthernIreland 2024-02-01 2025-02-28 NI709560 core:FurnitureFittings 2024-02-01 2025-02-28 NI709560 core:ComputerEquipment 2024-02-01 2025-02-28 NI709560 core:FurnitureFittings 2024-01-31 NI709560 core:ComputerEquipment 2024-01-31 NI709560 core:FurnitureFittings 2025-02-28 NI709560 core:ComputerEquipment 2025-02-28 iso4217:GBP xbrli:pure
Company Registration No. NI709560 (Northern Ireland)
Antigenesis Biologics Ltd Unaudited accounts for the period from 1 February 2024 to 28 February 2025
Antigenesis Biologics Ltd Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
Antigenesis Biologics Ltd Company Information for the period from 1 February 2024 to 28 February 2025
Directors
Mr Terence Hugh Brannigan Dr Ciaran Patrick Anthony Doherty Dr Hugh Patrick Morgan
Company Number
NI709560 (Northern Ireland)
Registered Office
78 Teconnaught Road Crossgar Downpatrick County Down BT30 9HH Northern Ireland
Accountants
Nuvem 9 Ltd The Mount Business Centre Woodstock Link Belfast County Antrim BT6 8DD
- 3 -
Antigenesis Biologics Ltd Statement of financial position as at 28 February 2025
2025
Notes
£
Fixed assets
Tangible assets
4
23,012
Current assets
Debtors
5
20,980
Cash at bank and in hand
31,350
52,330
Creditors: amounts falling due within one year
6
(9,255)
Net current assets
43,075
Net assets
66,087
Capital and reserves
Called up share capital
10
Share premium
50,000
Profit and loss account
16,077
Shareholders' funds
66,087
For the period ending 28 February 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 22 October 2025 and were signed on its behalf by
Dr Hugh Patrick Morgan Director Company Registration No. NI709560
- 4 -
Antigenesis Biologics Ltd Notes to the Accounts for the period from 1 February 2024 to 28 February 2025
1
Statutory information
Antigenesis Biologics Ltd is a private company, limited by shares, registered in Northern Ireland, registration number NI709560. The registered office is 78 Teconnaught Road, Crossgar, Downpatrick, County Down, BT30 9HH, Northern Ireland.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous period, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Fixtures & fittings
5 year straight line
Computer equipment
3 year straight line
4
Tangible fixed assets
Fixtures & fittings
Computer equipment
Total
£
£
£
Cost or valuation
At cost
At cost
At 1 February 2024
-
2,757
2,757
Additions
20,847
-
20,847
At 28 February 2025
20,847
2,757
23,604
Depreciation
At 1 February 2024
-
329
329
Charge for the period
263
-
263
At 28 February 2025
263
329
592
Net book value
At 28 February 2025
20,584
2,428
23,012
- 5 -
Antigenesis Biologics Ltd Notes to the Accounts for the period from 1 February 2024 to 28 February 2025
5
Debtors
2025
£
Amounts falling due within one year
VAT
13,007
Trade debtors
1,500
Accrued income and prepayments
6,463
Other debtors
10
20,980
6
Creditors: amounts falling due within one year
2025
£
Trade creditors
6,216
Taxes and social security
1,039
Accruals
2,000
9,255
7
Average number of employees
During the period the average number of employees was 2.
- 6 -